RBC Capital lowered the firm’s price target on Teleflex (TFX) to $245 from $275 and keeps an Outperform rating on the shares. The company’s Q3 revenue miss reflects a surprise OEM customer loss, and UroLift softness, though the firm maintains that Teleflex business fundamentals are intact and margin expansion is on track, the analyst tells investors in a research note.